TOPIGEN INITIATES PHASE II ASTHMA TRIAL

Topigen Pharmaceuticals has announced the initiation of a Phase II clinical trial of ASM8 in patients with allergic asthma.

The randomized, placebo-controlled, multicenter, crossover, Phase II trial will assess the efficacy and overall safety and tolerability of ASM8. The study in mild allergic asthmatics will evaluate repeated administration of ASM8 in patients for the treatment of allergen-induced asthma.

ASM8 is a first-in-class drug that combines two oligonucleotides into a single product delivered directly to the site of cellular action. This approach of inhibiting multiple pathways by blocking the expression of specific genes may have many advantages over current asthma medications.